STAT

NOVEMBER 18, 2023

It wasn’t until January 2013 that the first paper showing the enzyme would work in cells, from Feng Zhang, was published, also in Science. Jennifer Doudna and Emmanuelle Charpentier, now Nobelists , published their first paper announcing a new enzyme for editing DNA in Science in June 2012. It was called CRISPR-Cas9.

358

358

STAT

FEBRUARY 12, 2024

Over the past decade, the number of research misconduct allegations reported to the National Institutes of Health has more than doubled, climbing from 74 in 2013 to 169 in 2022. And it’s hardly alone. And scientific sleuths are finding plenty of other problems that don’t always qualify as outright misconduct.

349

349

STAT

DECEMBER 8, 2023

Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics were all started in the 2013-2014 time frame with the same goal of turning the nascent CRISPR gene-editing technology into medicines.

298

298

STAT

OCTOBER 11, 2023

So far this year, there have been 1,384 VC deals struck in the field, the lowest figure since 2013. New data from Pitchbook and the National Venture Capital Association show that both the number of deals and the amount of money that’s being invested in life science companies are down significantly.

311

311

pharmaphorum

APRIL 8, 2024

Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years

93

93

STAT

DECEMBER 20, 2022

For example, the share of Mexican Americans taking insulin who achieved good blood-sugar control sharply dropped to 10% during the period of 2013 to 2020 from 25% during 1988 to 1994, researchers reported Tuesday in JAMA Network Open. Read the rest…

Diabetes 225

Diabetes 225

STAT

SEPTEMBER 28, 2023

million from 2013 to 2019, presumably due to the company payments, according to the study, which was published in JAMA Health Forum. Physicians who did not accept payments prescribed Avastin 46% of the time, nearly twice as often as those who accepted payments. As a result, Medicare shelled out an estimated $642.8

283

283

STAT

NOVEMBER 10, 2022

He has been part of the C-suite at Sage Therapeutics since 2013. Longtime Sage Therapeutics executive Jeff Jonas is leaving the biotech company to launch a biotech incubator with global investment giant CBC Group. Sage announced this week that Jonas would leave the company to join a private equity firm. billion deal with Biogen.

237

237

STAT

MAY 19, 2023

Founded in 2013, Pear was the most prominent company developing prescription digital therapeutics, or Food and Drug Administration-cleared software applications ordered by doctors to treat health conditions. Click Therapeutics, Welt Corp, Harvest Bio, and Nox Health Group each acquired bits of the company for $6.05

308

308

STAT

MAY 1, 2023

San Francisco-based Carbon said that Elevance — formerly known as Anthem, which operates the Anthem Blue Cross plan in California — had refused to increase its payment rate in the state beyond 2013 levels, which was “no longer tenable as a livable wage.” ” Continue to STAT+ to read the full story…

195

195

STAT

JANUARY 17, 2024

Central Texas’ Scott and White was absorbed into Baylor in 2013. Wisconsin’s Marshfield Clinic agreed to merge with Duluth-based Essentia Health in October 2022 after a lengthy string of operating losses, though the merger fell apart recently.

Hospitals 325

Hospitals 325

STAT

JANUARY 8, 2024

The two men worked together from 2013 until 2022, when Jonas left to start a biotech incubator with funding from investment giant CBC Group. The VC firm has hired Jeff Jonas, Sage’s former chief executive, and Al Robichaud, Sage’s former chief scientific officer, as partners, the team told STAT exclusively.

Labelling 231

Labelling 231

STAT

MAY 15, 2023

Hospitals ran short of essential treatment medications and were unable to source those drugs from manufacturers or from the outsourcing facilities that had been authorized by Congress in 2013 to “fill the gap” in such situations.

Compounding Pharmacies 231

Compounding Pharmacies Compounding Hospitals 231

STAT

MARCH 9, 2023

In the spring of 2013, I had just visited a lab focused on gene and cell therapies at Baylor College of Medicine. Bluebird Bio , which would soon launch a successful IPO , had licensed its technology from the same lab and was about to announce a major collaboration with Celgene and Baylor.

203

203

STAT

OCTOBER 12, 2022

A federal law that went into effect in 2013 requires the FDA to identify ingredients needed to satisfy an unmet “clinical need” and to include those on  a list for use by large compounding pharmacies.

Compounding Pharmacies 213

Compounding Pharmacies Compounding 213

STAT

DECEMBER 13, 2022

When it hit the market in 2013, the drug revolutionized the treatment of these cancers and represented a major step forward from chemotherapy and some other drugs at the time. NEW ORLEANS – One of the best therapies for some types of lymphoma and leukemia has been a drug called ibrutinib, made by AbbVie.

Chemotherapy 212

Chemotherapy 212

STAT

AUGUST 24, 2023

Indeed, on July 1, drugmakers raised the wholesale price on over 123 drugs in what’s the largest number of mid-year price hikes since 2013, according to data from drug pricing nonprofit 46brooklyn and the Elsevier Gold Standard Drug Database. Continue to STAT+ to read the full story…

Drug Pricing 209

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 209

STAT

AUGUST 3, 2023

In his 2013 State of the Union address, he laid out a bold vision to fund and accelerate brain research: “If we want to make the best products, we also have to invest in the best ideas.

231

231

STAT

AUGUST 30, 2023

In 2013, Kevan Shokat, a biologist at the University of California, San Francisco, discovered a key chemical vulnerability in a specific subset of mutant oncogenic KRAS that made it possible to design small molecules that would bind to the protein. ” In the last few years, that attitude has sharply turned around.

Drug Development 220

Drug Development 220

STAT

APRIL 5, 2023

are charged with knowingly selling defective lead testing machines between 2013 and 2017 that generated inaccurate results for tens of thousands of children across the country and for clients of at least one international relief organization, federal prosecutors said. Three former executives at Magellan Diagnostics Inc.

183

183

European Pharmaceutical Review

FEBRUARY 23, 2024

Richard Gonzalez will retire as the company’s CEO to become Executive Chairman, having served as the company’s CEO since its launch in 2013, AbbVie noted. Richard has facilitated AbbVie securing a market capitalisation increase from $54 billion in 2013 to over $300 billion in 2024.

Hospitals 81

Hospitals 81

Med Ed 101

OCTOBER 4, 2023

It’s hard to believe that I have been following pharmacist board certifications and helping pharmacists pass the BCPS exam for over 10 years since I first passed it in 2013! Each year in updating and creating our study materials, I review the content outline and any possible changes in the BCPS exam.

111

111

Pharmaceutical Technology

MARCH 12, 2024

Butterworth Laboratories looks at the current amino acid testing landscape since the changes in monographs introduced in 2013.

52

52

ALiEM - Pharm Pearls

FEBRUARY 20, 2024

2013 Dec;15(4):90-2. Epub 2013 Nov 7. Sivalingam SK, Gadiraju VT, Hariharan MV, Atreya AR, Flack JE, Aziz H. Flecainide toxicity–treatment with intravenous fat emulsion and extra corporeal life support. Acute Card Care. doi: 10.3109/17482941.2013.841949. PMID: 24200150. Bruccoleri RE, Burns MM. J Med Toxicol.

177

177

ALiEM - Pharm Pearls

NOVEMBER 10, 2023

2013 Apr;168(4):726-32. Epub 2013 Feb 16. PMID: 34212341 Lipowicz S, Sekula P, Ingen-Housz-Oro S, Liss Y, Sassolas B, Dunant A, Roujeau JC, Mockenhaupt M. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. doi: 10.1111/bjd.12133. PMID: 23413807.

156

156

STAT

JUNE 20, 2023

A 2013 trial of the first iteration of Cologuard, known as DeeP-C, showed the test is 92% sensitive and 87% specific. The new Cologuard test correctly detected cancer 94% of the time, and it correctly returned a negative result 91% of the time, test characteristics known as sensitivity and specificity, respectively.

185

185

STAT

NOVEMBER 7, 2023

In August 2013, the FDA made news when it issued cybersecurity guidance for medical devices.

198

198

STAT

MARCH 29, 2024

From 2013 to 2022, pharmaceutical and device companies made more than 85 million payments totaling $12.1 Financial ties between drug and device makers and some physicians remain pervasive, despite concerns such relationships may influence medical practice , STAT writes, citing a new analysis of payments made over a recent 10-year span.

229

229

Express Pharma

MARCH 12, 2024

Note: Includes all announced and completed deals for target companies headquartered in the US from 2013-2023 as a percentage growth from the baseline year 2013. Includes deals where at least one drug involved is an innovator for Marketed, Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery development stages.

99

99

Pharmacy Times

DECEMBER 4, 2023

in 2013 to 19.3% The proportion of prescriptions by a 340B-affiliated physician increased from 9.4% in 2020, but the prescriptions filled by 340B pharmacies increased from 18.4% to 49.9%.

Prescription Filling 48

Prescription Filling 48

PhRMA

JANUARY 5, 2023

The study finds that since curative direct-acting antiviral medications for hepatitis C were approved in 2013, even after factoring in the cost of treatment, Medicaid has saved an estimated $15 billion in avoided health care costs and nearly 285,000 Medicaid enrollees are estimated to have been cured.

84

84

Express Pharma

NOVEMBER 3, 2023

Saroglitazar Mg was launched in India in September 2013 for the treatment of diabetic dyslipidemia and hypertriglyceridemia in patients with type-2 diabetes not controlled by statins alone. Zydus launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them.

Diabetes 103

Diabetes 103

ALiEM - Pharm Pearls

MARCH 5, 2024

2013 May;5(5):330. Phytotherapy Research. 2015;29(8):1112-1116. PMID: 25997859. Srivali N, Cheungpasitporn W, Chongnarungsin D, Edmonds LC. White willow bark induced acute respiratory distress syndrome. N Am J Med Sci. PMID: 23814765. Kuzak N, Brubacher JR, Kennedy JR. Reversal of salicylate-induced euglycemic delirium with dextrose.

Clinical Pharmacology 280

Clinical Pharmacology Adverse Reactions Compounding 280

ALiEM - Pharm Pearls

MAY 17, 2023

The 2013 to 2019 Emergency Medicine Workforce: Clinician Entry and Attrition Across the US Geography. The Emergency Medicine Physician Workforce: Projections for 2030. Ann Emerg Med. 2021;78(6):726-737. doi: 10.1016/j.annemergmed.2021.05.029 2021.05.029 Gettel CJ, Courtney DM, Janke AT, Rothenberg C, Mills AM, Sun W, Venkatesh AK.

130

130

Pharmacy Times

MARCH 11, 2024

The early phase clinical trial, which ended prematurely in 2013 due to funding challenges, further illustrates disparities in health equity in clinical research.

20

20

World Pharma News

APRIL 21, 2023

Alarmingly, since 2013, the world-wide prevalence of MS has risen by 30%. The Atlas of MS reported in 2020 that someone is diagnosed with MS every five minutes around the world, adding to about 2.8 million individuals that currently have to live with the disease.

Communication 65

Communication 65

pharmaphorum

MARCH 10, 2022

It says the price increases were imposed “as though a new version of Acthar came on the market in 2013, when in fact, it did not,” which allowed it to ignore all price increases prior to 2013 in its rebate calculations.

Drug Pricing 99

Drug Pricing Pharmaceutical Manufacturing 99